← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors
siltuximab
L04AC11
Forms & Strengths
- 100 mg/5 mL single-use vial for IV infusion
- 200 mg/10 mL single-use vial for IV infusion
- 400 mg/20 mL single-use vial for IV infusion
Adult Dosing
- For Castleman's disease: 11 mg/kg IV infusion every 3 weeks
- For multicentric Castleman's disease: 11 mg/kg IV infusion every 3 weeks
- For other off-label uses: dosing may vary, consult clinical guidelines
Pediatric Dosing
- For pediatric patients with Castleman's disease: 11 mg/kg IV infusion every 3 weeks, but use with caution due to limited data
- For pediatric patients less than 18 years: limited data available, consult clinical guidelines
Indications
- Treatment of multicentric Castleman's disease
- Treatment of Castleman's disease that is human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative
Mechanism of Action
- Siltuximab is an immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to human interleukin-6 (IL-6)
- Binding of siltuximab to IL-6 prevents IL-6 from interacting with its receptors, thereby inhibiting IL-6 mediated signaling
Contraindications
- Hypersensitivity to siltuximab or any of the excipients
- Severe hypersensitivity reactions to siltuximab
Adverse Reactions
- Hypertension
- Diarrhea
- Thrombocytopenia
- Increased liver enzymes
- Pruritus
- Hypertriglyceridemia
- Infusion reaction
- Fatigue
Drug Interactions
- Increased risk of gastrointestinal perforation with concomitant use of siltuximab and corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs)
- Live vaccines: do not administer live or live attenuated vaccines to patients receiving siltuximab or within 4 weeks before starting therapy
- Concomitant use of siltuximab with other immunosuppressive or immunomodulatory agents may increase risk of infection
Curated Content: Needs Vetting Before Put to Clinical Use